Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

European Medicines Agency backs gene therapy to treat rare bleeding disorder

The European Union's health regulator on Friday said it had recommended granting a conditional marketing authorization for a gene therapy by Australian drugmaker CSL Ltd and partner uniQure N.V. , to treat haemophilia B, a rare bleeding disorder which is caused by genetic anomalies.

About one in 40,000 people are affected by the inherited disorder, caused by a gene mutation that hampers the body's ability to make clotting protein factor IX.


If approved, the treatment, branded Hemgenix, will be the first gene therapy in the European Union for the condition that is usually treated by regular injections of factor IX, the European Medicines Agency said.

CSL had acquired exclusive global rights to Hemgenix in May last year from uniQure N.V.

In November, the U.S. Food and Drug Administration approved Hemgenix for the treatment of rare genetic blood clotting disorder, followed by CSL Ltd setting the list price of the therapy at $3.5 million making it the world's most expensive treatment.

More For You

NHS to invest millions to boost enhanced treatment for sickle cell patients

Approximately 17,000 people live in England with sickle cell disease

Pic credit: istock

NHS to invest millions to boost enhanced treatment for sickle cell patients

The Department of Health and Social Care has announced that it will invest £9 million towards the treatment of sickle cell patients.

Approximately 17,000 people live in England with sickle cell disease. Nearly 250 new cases of this inherited blood disorder is reported annually.

Keep ReadingShow less
NHS leads the world with new ‘trojan horse’ therapy for blood cancer patients

An estimated 6,000 cases of multiple myeloma is diagnosed in the UK each year.

Pic credit: istock

NHS leads the world with new ‘trojan horse’ therapy for blood cancer patients


NHS England has become the first in the world to introduce a ‘trojan horse’ therapy for the victims of blood cancer with the ground-breaking treatment slowing down the illness three-times more than existing treatments.

Keep ReadingShow less
Call to improve inclusivity in clinical research

Ethnic minority adults continue to be underrepresented in clinical trials.

iStock

Call to improve inclusivity in clinical research

A NEW report has called for the participation of a wide range of diverse communities in clinical research to make sure that the medicines meet the needs of the UK's increasingly diverse population.

The report ‘Achieving inclusivity in clinical research’, prepared by the Association of the British Pharmaceutical Industry (ABPI) and the Association of Medical Research Charities (AMRC), highlights the long-standing challenges in ensuring diversity in clinical trials.

Keep ReadingShow less
Pharmacy students Learning Support Fund

Pharmacy students will be included in the Travel and Dual Accommodation Expenses section of the NHS Learning Support Fund.

iStock

Pharmacy students to have access to Learning Support Fund

FOR the first time in England, pharmacy students will be eligible to reimburse travel and accommodation costs while attending placements.

The Department of Health and Social Care confirmed that pharmacy students would finally be included in the Travel and Dual Accommodation Expenses (TDAE) section of the NHS Learning Support Fund (LSF).

Keep ReadingShow less
NHS for robotic surgery

Patients undergoing robotic surgery are able to recover quicker and be discharged sooner.

Pic credit: iStock

NHS pushes for robotic surgery to reduce waiting time, improve outcomes

The NHS is planning to step up robotic surgery over the next decade to reduce waiting time, help in the speed of recovery of patients, and shorter hospital stay.

As per the NHS projections, the number is expected to zoom from 70,000 in 2023/24 to half a million by 2035.

Keep ReadingShow less